摘要
目的评估国产注射用甲磺酸齐拉西酮对首发精神分裂症患者急性期激越症状的安全性及疗效。方法给予42例具有急性期激越症状住院治疗的首发精神分裂症患者肌内注射甲磺酸齐拉西酮10~20 mg/次,根据病情4~6 h后可重复使用,总剂量不超过40 mg/d,疗程3 d。治疗后24 h、48 h及72 h给予PANSS、冲动、自杀、出走风险评估表评分评定疗效及风险;采用药TESS以及心电图、实验室检查评估药物不良反应。结果治疗后PANSS评分逐渐下降,均明显低于治疗前(P <0.01);出现不良反应11例(26.19%)。结论国产注射用甲磺酸齐拉西酮注射液在首发精神分裂症的急性激越控制上有较好的安全性与疗效。
Objective To evaluate the safety and efficacy of domestic ziprasidone mesylate injection on acute agitated symptoms in patients with first-onset schizophrenia. Methods 42 first-episode schizophrenia patients with acute agitated symptoms were given intramuscular injections of ziprasidone mesylate 10 ~ 20 mg/time which could be reuse after 4 ~ 6 hours according to the condition and and total dose was no more than 40 mg/d,the course of treatment was 3 d. 24,48 and 72 hours after treatment,the positive and negative symptom scale( PANSS),impulsivity,suicide,and running away risk assessment scores were given to evaluate the efficacy and risk;Adverse Drug Reaction Scale( TESS),electrocardiogram,and laboratory tests were used to evaluate the drug adverse reactions. Results After the treatment,the PANSS score decreased gradually,and were significantly lower than that before treatment( P < 0. 01);11 cases( 26. 19%) had adverse reactions( 26. 19%). Conclusions Domestic ziprasidone mesylate injection has good safety and efficacy in the acute agitation control of first-episode schizophrenia.
作者
黄江
韦伟香
张培浩
宁小宇
杨胜兰
HUANG Jiang;WEI Wei-xiang;ZHANG Pei-hao;NING Xiao-yu;YANG Sheng-lan(Department of psychiatry,The Second Affiliated Hospital of Guizhou Medical University,Kaili Guizhou 556000,China)
出处
《云南医药》
2022年第1期20-23,共4页
Medicine and Pharmacy of Yunnan
